Power Law company profile

Immunocore

Biotech & Life Sciences · Milton, United Kingdom · Founded 2008 · IPO 2021 Unicorn

TCR bispecific immunotherapies for cancer and infectious diseases

Valuation

$991M

Market cap · May/2026

Revenue

$402M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

12 investors on Immunocore's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage

RTW Investments

Woodford Investment Management

Eli Lilly

Series B+ 9 investors entered at this stage

General Atlantic

WuXi Healthcare Ventures

University of Oxford

Omega Funds

Rock Springs Capital

JDRF T1D Fund

BlackRock

Bill & Melinda Gates Foundation

CCB International

Immunocore mafia

Startups founded by Immunocore alumni

Former Immunocore employees who went on to start their own companies. Sorted by Dealroom signal score.

Accession TherapeuticsEst. 2020

Bent JakobsenUnited Kingdom

Signal score81

AdaptimmuneEst. 2008

James NobleUnited Kingdom

Signal score63

Zelluna ImmunotherapyEst. 2016

NHNamir HassanNorway

Signal score58

Yellowstone BiosciencesEst. 2023

Julian HirstUnited Kingdom

Signal score56

invIOsEst. 2022

PLPeter Llewellyn-DaviesAustria

Signal score55

Ducentis BioTherapeuticsEst. 2015

RARebecca AshfieldUnited Kingdom

Signal score47

Book a demo to explore the full alumni network →

Global footprint

Where Immunocore has talent and traffic

AI talent share

0.3% of workforce is AI talent
(2 of 587 staff)

Core AI10.17%

Other AI10.17%

Non-AI workforce58599.66%

Workforce by country

8 countries with
team presence

🇬🇧 United Kingdom65.3%

🇺🇸 United States32.5%

🇮🇪 Ireland0.9%

🇪🇸 Spain0.4%

🇨🇭 Switzerland0.2%

Top 5 of 8 shown

Web traffic by country

12K monthly visits
across markets

🇺🇸 United States47.5%

🇬🇧 United Kingdom36.7%

🇮🇳 India7.5%

🇨🇭 Switzerland6.7%

🇩🇪 Germany0.8%

Top 5 markets shown

Patent intelligence

$98M patent portfolio · 59 active families

Estimated portfolio value

$98M

9.9% of market cap · 72.4× smaller than top peer Janssen Vaccines ($7.1B)

59 active patent families

Where Immunocore innovates Cellular receptorCancer researchT-cell AntigenCarcinosisPharmacology

Where Immunocore concentrates vs peers

Each axis is a top-10 topic across Immunocore and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Immunocore

An AI-synthesized read of the highest-engagement posts about Immunocore on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Immunocore on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles